Supernus Pharmaceuticals, Inc. (SUPN) has reached a definitive agreement to acquire Sage Therapeutics, Inc. through a cash tender offer of $8.50 per share.
Jack Khattar, President and CEO of Supernus Pharmaceuticals (SUPN), noted that this acquisition adds a significant fourth growth product to their portfolio, enhancing their growth profile.
The deal also expands their sources of future growth.
He highlighted that ZURZUVAE aligns well with their strategy of acquiring novel, value-enhancing, and clinically differentiated medicines for CNS conditions.
Supernus Pharmaceuticals (SUPN) plans to provide updated full-year financial guidance for 2025 after the transaction closes.
The closing is expected in the third quarter of 2025.
The acquisition is projected to be substantially accretive in 2026.